Denali Therapeutics DNLI
NASDAQ DNLI
$22.31 -0.49 (-2.16%)
As of: Sep 4, 2026 · 1:39 PM EDT

Denali Therapeutics (DNLI) Amortizatization of Intangibles (2024 - 2026)

Denali Therapeutics (DNLI) posted quarterly Amortizatization of Intangibles of $916000.0 for Q1 2026, up 3.27% year-over-year from $887000.0 in Q1 2025, and little changed quarter-over-quarter from $916000.0 in Q4 2025.

Analysis

Denali Therapeutics (DNLI) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends

Denali Therapeutics (DNLI) has reported Amortizatization of Intangibles for 3 consecutive years, with $916000.0 the latest figure, recorded in Q1 2026.

  • In Q1 2026, Amortizatization of Intangibles rose 3.27% year-over-year to $916000.0; the TTM figure through Mar 2026 stood at $3.6 million (up 74.28% YoY), while the FY2025 annual figure was $3.6 million, up 203.17% from the prior year.
  • Amortizatization of Intangibles held at $916000.0 in Q1 2026 per DNLI's latest filing, from $916000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $916000.0 in Q4 2025 and bottomed at $400000.0 in Q3 2024.
  • Historically, Amortizatization of Intangibles has averaged $816571.4 across 3 years, with a median of $900000.0 in 2025.
  • Annual changes were most pronounced in 2025 — Amortizatization of Intangibles surged 125.0% — and 2026, when it grew 3.27%.
  • Denali Therapeutics' Amortizatization of Intangibles stood at $797000.0 in 2024, then increased by 14.93% to $916000.0 in 2025, then changed by 0.0% to $916000.0 in 2026.
  • Business Quant data shows DNLI's Amortizatization of Intangibles at $916000.0 in Q1 2026, $916000.0 in Q4 2025, and $900000.0 in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn -
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - 4.33 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn -
8 Royalty Pharma 28.44 Bn 27.60 Bn - -
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 678,000.00
10 Denali Therapeutics 4.18 Bn 4.18 Bn 3.51 Mn 915,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 915,000.00
Mar 31, 2026 916,000.00
Dec 31, 2025 916,000.00
Sep 30, 2025 900,000.00
Jun 30, 2025 911,000.00
Mar 31, 2025 887,000.00
Dec 31, 2024 766,000.00
Sep 30, 2024 400,000.00